Basal Cell Carcinoma - Pipeline Review, H1 2017

  • ID: 4245297
  • Report
  • 121 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BLR Bio LLC
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • MediGene AG
  • Merck & Co Inc
  • MORE
Basal Cell Carcinoma - Pipeline Review, H1 2017

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 6 respectively.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BLR Bio LLC
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • MediGene AG
  • Merck & Co Inc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development

Biosceptre International Ltd

BLR Bio LLC

Cannabis Science Inc

Genextra Spa

Ignyta Inc

Laboratories Ojer Pharma SL

MediGene AG

Merck & Co Inc

Provectus Biopharmaceuticals Inc

Redx Pharma Plc

Regeneron Pharmaceuticals Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Transgene SA

Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-010t - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-S/BCC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTATI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAC-060 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oshadi D + Oshadi R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PV-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2810 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sinecatechins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-1042 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones

Featured News & Press Releases

Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma

Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by BLR Bio LLC, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra Spa, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta Inc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2017

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll